Skip to content

Released Mar 30, 2023, after the close

10-K filed Mar 30, 2023, 89 days after period end · 0000950170-23-010976

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$8.63Mderived−19.0% vs Q4 2021−65.7% vs Q3 2022
Net Income-$34.59MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$49,222,000N/M
Operating Cash Flowderived-$23,864,000N/M
Margins · derived
Operating margin-570.2%−241.4 pt vs Q4 2021
Net margin-400.8%−42.9 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020Q4 2019
Revenue$8.63M$10.65M$8.28M$11.31M
Net Income-$34.59M-$38.13M-$59.54M-$14.79M
EPS Diluted——-$1.48-$0.65

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR